Japan's Otsuka Pharma to pay up to $1.1 bln to acquire Jnana Therapeutics (updated)
Japan's Otsuka Pharma to pay up to $1.1 bln to acquire Jnana Therapeutics
Otsuka Pharmaceutical To Acquire Jnana Therapeutics
To Buy Back Up To 1.84% Of Own Shares Worth 50 Billion Yen
2024 6-month group forecast(IFRS)
Japan's Otsuka to stop development of Alzheimer's disease drug (updated)
Otsuka to stop development of Alzheimer's disease drug
2024 6-month group forecast(IFRS)
Table: Otsuka Holdings -Q1 group results (IFRS)
Otsuka And Lundbeck Submit SNDA For FDA Review Of Brexpiprazole And Sertraline Combination As Potential Treatment For Ptsd
Brief: Otsuka Pharmaceutical Announces U.S. FDA Clearance Of Rejoyn
Enters Into An Agreement To Amend Worldwide Collaboration And License For Four Compounds Including Ulotaront With Otsuka
Table: Otsuka Holdings -2023 group results (IFRS)
Table: Otsuka Holdings -2023 group forecast(IFRS)
Otsuka's drug for Alzheimer's disease agitation fails in late stage study
Ostsukaa Announces Phase 3 Topline Results Of AVP-786 In Treatment Of Agitation Associated With Dementia Due To Alzheimer's Disease
Otsuka Obtains Additional Indication Of Adjunctive Treatment Of Major Depressive Disorder For Rexulti In Japan
Pharmavite, A U.S. Subsidiary Of Otsuka Pharmaceutical, Acquires Bonafide Health, A Provider Of Women's Health Products
Media: Nature Made vitamins owner buys Bonafide Health for $425 million - Bloomberg News